{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T04:20:54Z","timestamp":1690258854750},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00108-023-01547-5","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T07:02:06Z","timestamp":1689058926000},"page":"815-818","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Baricitinib bei systemischem Lupus erythematodes","Baricitinib for systemic lupus erythematosus"],"prefix":"10.1007","volume":"64","author":[{"given":"M.","family":"Aringer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Nitschmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,11]]},"reference":[{"key":"1547_CR1","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/art.24449","volume":"60","author":"T Karonitsch","year":"2009","unstructured":"Karonitsch\u00a0T, Feierl\u00a0E, Steiner\u00a0CW et al (2009) Activation of the interferon-gamma signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells. Arthritis Rheum 60:1463\u20131471","journal-title":"Arthritis Rheum"},{"key":"1547_CR2","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/art.27221","volume":"62","author":"GG Illei","year":"2010","unstructured":"Illei\u00a0GG, Shirota\u00a0Y, Yarboro\u00a0CH et al (2010) Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 62:542\u2013552","journal-title":"Arthritis Rheum"},{"key":"1547_CR3","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1093\/rheumatology\/40.8.876","volume":"40","author":"M Aringer","year":"2001","unstructured":"Aringer\u00a0M, Stummvoll\u00a0GH, Steiner\u00a0G et al (2001) Serum interleukin-15 is elevated in systemic lupus erythematosus. Rheumatology 40:876\u2013881","journal-title":"Rheumatology"},{"issue":"i4","key":"1547_CR4","first-page":"i16","volume":"58","author":"M Gadina","year":"2019","unstructured":"Gadina\u00a0M, Le\u00a0MT, Schwartz\u00a0DM et\u00a0al (2019) Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatology 58(i4):i16","journal-title":"Rheumatology"},{"key":"1547_CR5","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","volume":"392","author":"DJ Wallace","year":"2018","unstructured":"Wallace\u00a0DJ, Furie\u00a0RA, Tanaka\u00a0Y et al (2018) Baricitinib for systemic lupus erythematosus: a\u00a0double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 392:222\u2013231","journal-title":"Lancet"},{"key":"1547_CR6","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","volume":"401","author":"EF Morand","year":"2023","unstructured":"Morand\u00a0EF, Vital\u00a0EM, Petri\u00a0M et al (2023) Baricitinib for systemic lupus erythematosus: a\u00a0double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet 401:1001\u20131010","journal-title":"Lancet"},{"key":"1547_CR7","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","volume":"401","author":"M Petri","year":"2023","unstructured":"Petri\u00a0M, Bruce\u00a0IN, D\u00f6rner\u00a0T et al (2023) Baricitinib for systemic lupus erythematosus: a\u00a0double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet 401:1011\u20131019","journal-title":"Lancet"},{"key":"1547_CR8","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1136\/annrheumdis-2022-222335","volume":"81","author":"T D\u00f6rner","year":"2022","unstructured":"D\u00f6rner\u00a0T, Tanaka\u00a0Y, Dow\u00a0ER et\u00a0al (2022) Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus. Ann Rheum Dis 81:1267\u20131272","journal-title":"Ann Rheum Dis"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-023-01547-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-023-01547-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-023-01547-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T07:02:34Z","timestamp":1690182154000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-023-01547-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,11]]},"references-count":8,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1547"],"URL":"https:\/\/doi.org\/10.1007\/s00108-023-01547-5","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,11]]},"assertion":[{"value":"22 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M. Aringer: Advisory Boards und\/oder Vortr\u00e4ge f\u00fcr AbbVie, Astra Zeneca, Galapagos, GSK, Lilly, Pfizer. S.\u00a0Nitschmann gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}